Å. Bratland
Oslo University Hospital(NO)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Head and Neck Cancer Studies, Nonmelanoma Skin Cancer Studies, Lung Cancer Diagnosis and Treatment, Cutaneous Melanoma Detection and Management
Most-Cited Works
- → Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial(2021)187 cited
- → KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)(2018)134 cited
- → 915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)(2020)11 cited
- → Radiotherapy quality assurance of patients with squamous cell carcinoma of the head and neck included in the DAHANCA 19 randomised phase III trial(2025)1 cited
- → Pembrolizumab for Locally Advanced or Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma: Long-Term Results of the Phase 2 Keynote-629 Study(2024)1 cited
- → PH-0048 Pattern of failure after curative (C-)RT in HNSCC: data from the phase III DAHANCA19 study(2021)
- → Abstract PO-009: Phase 3 KEYNOTE-630 study of adjuvant pembrolizumab in high-risk locally advanced cutaneous squamous cell carcinoma(2023)